Checkpoint Therapeutics, Inc. (CKPT)
NASDAQ: CKPT · IEX Real-Time Price · USD
1.430
+0.010 (0.70%)
At close: Apr 26, 2024, 4:00 PM
1.530
+0.100 (6.99%)
After-hours: Apr 26, 2024, 6:52 PM EDT
Checkpoint Therapeutics Revenue
In the year 2023, Checkpoint Therapeutics had annual revenue of $103.00K, a decrease of -46.35%. Revenue in the quarter ending December 31, 2023 was $6.00K, a -91.89% decrease year-over-year.
Revenue (ttm)
$103.00K
Revenue Growth
-46.35%
P/S Ratio
485.73
Revenue / Employee
$4,478
Employees
23
Market Cap
50.03M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 103.00K | -89.00K | -46.35% |
| Dec 31, 2022 | 192.00K | -76.00K | -28.36% |
| Dec 31, 2021 | 268.00K | -801.00K | -74.93% |
| Dec 31, 2020 | 1.07M | -639.00K | -37.41% |
| Dec 31, 2019 | 1.71M | -1.80M | -51.28% |
| Dec 31, 2018 | 3.51M | 1.78M | 103.25% |
| Dec 31, 2017 | 1.73M | -845.00K | -32.88% |
| Dec 31, 2016 | 2.57M | 1.98M | 335.59% |
| Dec 31, 2015 | 590.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.28B |
| NeueHealth | 1.16B |
| Apyx Medical | 52.35M |
| Jaguar Health | 9.76M |
| HCW Biologics | 560.36K |
| Gain Therapeutics | 55.18K |
CKPT News
- 22 hours ago - CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit - PRNewsWire
- 22 hours ago - DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm - Accesswire
- 23 hours ago - CKPT SHAREHOLDER ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT - Business Wire
- 3 days ago - CKPT Shareholders With Large Losses Should Contact Robbins LLP for Information About the Checkpoint Therapeutics, Inc. Class Action - Business Wire
- 4 days ago - SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm - PRNewsWire
- 5 days ago - DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm - Accesswire
- 7 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPT - PRNewsWire
- 7 days ago - ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT - PRNewsWire